Molbio Diagnostics 
Dealstreet

DMD Advocates, Roberts Zimmerman act on Molbio Diagnostics' $30 million investment in OptraSCAN

Molbio Diagnostics has gained a majority stake in OptraSCAN by making this investment.

Bar & Bench

Molbio Diagnostics has made a $30 million investment for acquiring a majority stake in OptraSCAN Inc., a US-based company specializing in digital pathology solutions.

DMD Advocates advised Molbio Diagnostics on this investment deal.

The transaction was led by Ayesha Rai (Partner) along with Pooja Shah (Principal Associate) and Vanshikha Choraria (Associate).

The legal due diligence team consisted of Kajal Tandon (Counsel), Luv Madan (Associate), Parizad Irani (Associate), and Tarush Bhandari (Associate).

Rashi Dhir (Senior Partner & Head of Corporate) and Vihang Virkar (Lead Partner) provided crucial inputs on the transaction.

Ayesha Rai, Rashi Dhir, Vihang Virkar

Roberts Zimmerman PLCC advised on US law related matters, with a team led by Ryan Roberts (Partner).

This acquisition enables Molbio to integrate OptraSCAN’s technology into its portfolio, strengthening its position in the diagnostics market both in India and internationally.

For OptraSCAN, the deal provides capital for growth and expansion while aligning its operations with Molbio’s strategic direction. This partnership enhances the capabilities of both companies, drives innovation, and increases their competitive edge in the healthcare and diagnostics sectors.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Producers of Tamil film Kaithi move Bombay HC accusing Bholaa's makers of violating remake rights

Deepika newspaper tenders apology before Kerala High Court for misleading report on court order

Delhi High Court denies relief to man accused of duping woman of ₹12 crore by selling fake DLF Camellias flat

Veritas Legal elevates Nainaaz Irani and Rohini Jaiswal to Partnership

Dr Reddy’s tells Delhi HC it will not launch oral diabetes drug within Novo Nordisk patent range

SCROLL FOR NEXT